Interleukin-17A in lipid metabolism and atherosclerosis

Clinica Chimica Acta

Volumn 431, Issue , 2014, Pages 33-39

  Yu, Xiao Hua ^a   Jiang, Na ^a   Zheng, Xi Long ^b   Cayabyab, Francisco S ^c   Tang, Zhi Bin ^a   Tang, Chao Ke ^a  

^a UNIVERSITY OF SOUTH CHINA   (China)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Atherosclerosis; IL 17A; IL 17RA; IL 17RC; Lipid metabolism

Indexed keywords

ARSENIC ACID DERIVATIVE; CCAAT ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 17; INTERLEUKIN 17 ANTIBODY; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 17 RECEPTOR A; INTERLEUKIN 17 RECEPTOR C; MESSENGER RNA; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CHRONIC INFLAMMATION; COMPLEX FORMATION; CYTOKINE RELEASE; DRUG TARGETING; GENE EXPRESSION REGULATION; HUMAN; INNATE IMMUNITY; LIPID METABOLISM; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION; RECEPTOR BINDING; REVIEW; RNA STABILITY; SIGNAL TRANSDUCTION; TH17 CELL; ANIMAL; BIOSYNTHESIS; GENETICS; METABOLISM; PHYSIOLOGY;

ANIMALS; ATHEROSCLEROSIS; HUMANS; INTERLEUKIN-17; LIPID METABOLISM; RECEPTORS, INTERLEUKIN-17; SIGNAL TRANSDUCTION;

EID: 84893898962     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.01.012     Document Type: Review

References (75)

1. Zhu S., Qian Y. IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential. Clin Sci (Lond) 2012, 122:487-511.
2. Su S.A., Ma H., Shen L., et al. Interleukin-17 and acute coronary syndrome. J Zhejiang Univ Sci B 2013, 14:664-669.
3. Gaffen S.L. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 2009, 9:556-567.
4. Toy D., Kugler D., Wolfson M., et al. Cutting edge: interleukin 17 signals through a heteromeric receptor complex. J Immunol 2006, 177:36-39.
5. Ely L.K., Fischer S., Garcia K.C. Structural basis of receptor sharing by interleukin 17 cytokines. Nat Immunol 2009, 10:1245-1251.
6. Liu S., Song X., Chrunyk B.A., et al. Crystal structures of interleukin 17A and its complex with IL-17 receptor A. Nat Commun 2013, 4:1888.
7. Esnault S., Kelly E.A., Nettenstrom L.M., et al. Human eosinophils release IL-1ss and increase expression of IL-17A in activated CD4+ T lymphocytes. Clin Exp Allergy 2012, 42:1756-1764.
8. Li N., Wang J.C., Liang T.H., et al. Pathologic finding of increased expression of interleukin-17 in the synovial tissue of rheumatoid arthritis patients. Int J Clin Exp Pathol 2013, 6:1375-1379.
9. Monteiro M., Almeida C.F., Agua-Doce A., et al. Induced IL-17-producing invariant NKT cells require activation in presence of TGF-beta and IL-1beta. J Immunol 2013, 190:805-811.
10. Zhou L., Ivanov I.I., Spolski R., et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007, 8:967-974.
11. Lilly L.M., Gessner M.A., Dunaway C.W., et al. The beta-glucan receptor dectin-1 promotes lung immunopathology during fungal allergy via IL-22. J Immunol 2012, 189:3653-3660.
12. Mudter J., Yu J., Zufferey C., et al. IRF4 regulates IL-17A promoter activity and controls RORgammat-dependent Th17 colitis in vivo. Inflamm Bowel Dis 2011, 17:1343-1358.
13. Du C., Liu C., Kang J., et al. MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nat Immunol 2009, 10:1252-1259.
14. Yao R., Ma Y.L., Liang W., et al. MicroRNA-155 modulates Treg and Th17 cells differentiation and Th17 cell function by targeting SOCS1. PLoS One 2012, 7:e46082.
15. Liu Y., Wang G.Y., Liu S.K., et al. beta-arrestin2 stimulates interleukin-17 production and expression of CD4+ T lymphocytes in a murine asthma model. Iran J Allergy Asthma Immunol 2011, 10:171-182.
16. Tsai H.C., Wu R. Cholera toxin directly enhances IL-17A production from human CD4+ T cells. J Immunol 2013, 191:4095-4102.
17. Kotla S., Singh N.K., Heckle M.R., et al. The Transcription Factor CREB Enhances Interleukin-17A Production and Inflammation in a Mouse Model of Atherosclerosis. Sci Signal 2013, 6:ra83.
18. Chalise J., Narendra S., Paudyal B., et al. Interferon alpha inhibits antigen-specific production of proinflammatory cytokines and enhances antigen-specific transforming growth factor beta production in antigen-induced arthritis. Arthritis Res Ther 2013, 15:R143.
19. Wang L., Wang J., Jin Y., et al. Oral Administration of All-Trans Retinoic Acid Suppresses Experimental Periodontitis by Modulating the Th17/Treg Imbalance. J Periodontol 2013, [Epub ahead of print].
20. Sun J., Zhao Y., Hu J. Curcumin inhibits imiquimod-induced psoriasis-like inflammation by inhibiting IL-1beta and IL-6 production in mice. PLoS One 2013, 8:e67078.
21. Chovanova L., Vlcek M., Krskova K., et al. Increased production of IL-6 and IL-17 in lipopolysaccharide-stimulated peripheral mononuclears from patients with rheumatoid arthritis. Gen Physiol Biophys 2013, 32:395-404.
22. Lu X.X., McCoy K.S., Hu W.K., et al. Dexamethasone reduces IL-17 and Tim-3 expression in BALF of asthmatic mice. J Huazhong Univ Sci Technolog Med Sci 2013, 33:479-484.
23. Bosmann M., Meta F., Ruemmler R., et al. Regulation of IL-17 family members by adrenal hormones during experimental sepsis in mice. Am J Pathol 2013, 182:1124-1130.
24. Unoda K., Doi Y., Nakajima H., et al. Eicosapentaenoic acid (EPA) induces peroxisome proliferator-activated receptors and ameliorates experimental autoimmune encephalomyelitis. J Neuroimmunol 2013, 256:7-12.
25. Miao T., Raymond M., Bhullar P., et al. Early growth response gene-2 controls IL-17 expression and Th17 differentiation by negatively regulating Batf. J Immunol 2013, 190:58-65.
26. Lee H.H., Yoon N.A., Vo M.T., et al. Tristetraprolin down-regulates IL-17 through mRNA destabilization. FEBS Lett 2012, 586:41-46.
27. Blalock E.L., Chien H., Dix R.D. Murine cytomegalovirus downregulates interleukin-17 in mice with retrovirus-induced immunosuppression that are susceptible to experimental cytomegalovirus retinitis. Cytokine 2013, 61:862-875.
28. Morzadec C., Macoch M., Robineau M., et al. Inorganic arsenic represses interleukin-17A expression in human activated Th17 lymphocytes. Toxicol Appl Pharmacol 2012, 262:217-222.
29. Gu C., Wu L., Li X. IL-17 family: Cytokines, receptors and signaling. Cytokine 2013, 64:477-485.
30. Chang S.H., Park H., Dong C. Act1 adaptor protein is an immediate and essential signaling component of interleukin-17 receptor. J Biol Chem 2006, 281:35603-35607.
31. Liu C., Qian W., Qian Y., et al. Act1, a U-box E3 ubiquitin ligase for IL-17 signaling. Sci Signal 2009, 2:ra63.
32. Zhu S., Pan W., Song X., et al. The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-alpha. Nat Med 2012, 18:1077-1086.
33. Lee S.J., Lee E.J., Kim S.H., et al. IL-17A promotes transdifferentiation of mouse myoblast cells (C2C12) into adipocytes by increasing the expression of peroxisome proliferator-activated receptor gamma through CAAT/enhancer binding protein beta signaling. Biotechnol Lett 2011, 33:229-235.
34. Zhang J., Qian X., Ning H., et al. Transcriptional suppression of IL-27 production by Mycobacterium tuberculosis-activated p38 MAPK via inhibition of AP-1 binding. J Immunol 2011, 186:5885-5895.
35. Hartupee J., Liu C., Novotny M., et al. IL-17 enhances chemokine gene expression through mRNA stabilization. J Immunol 2007, 179:4135-4141.
36. Bulek K., Liu C., Swaidani S., et al. The inducible kinase IKKi is required for IL-17-dependent signaling associated with neutrophilia and pulmonary inflammation. Nat Immunol 2011, 12:844-852.
37. Sun D., Novotny M., Bulek K., et al. Treatment with IL-17 prolongs the half-life of chemokine CXCL1 mRNA via the adaptor TRAF5 and the splicing-regulatory factor SF2 (ASF). Nat Immunol 2011, 12:853-860.
38. Herjan T., Yao P., Qian W., et al. HuR is required for IL-17-induced Act1-mediated CXCL1 and CXCL5 mRNA stabilization. J Immunol 2013, 191:640-649.
39. Qu F., Gao H., Zhu S., et al. TRAF6-dependent Act1 phosphorylation by the IkappaB kinase-related kinases suppresses interleukin-17-induced NF-kappaB activation. Mol Cell Biol 2012, 32:3925-3937.
40. Zhong B., Liu X., Wang X., et al. Negative regulation of IL-17-mediated signaling and inflammation by the ubiquitin-specific protease USP25. Nat Immunol 2012, 13:1110-1117.
41. Garg A.V., Ahmed M., Vallejo A.N., et al. The deubiquitinase A20 mediates feedback inhibition of interleukin-17 receptor signaling. Sci Signal 2013, 6:ra44.
42. Ho A.W., Garg A.V., Monin L., et al. The anaphase-promoting complex protein 5 (AnapC5) associates with A20 and inhibits IL-17-mediated signal transduction. PLoS One 2013, 8:e70168.
43. Zhu S., Pan W., Shi P., et al. Modulation of experimental autoimmune encephalomyelitis through TRAF3-mediated suppression of interleukin 17 receptor signaling. J Exp Med 2010, 207:2647-2662.
44. Zepp J.A., Liu C., Qian W., et al. Cutting edge: TNF receptor-associated factor 4 restricts IL-17-mediated pathology and signaling processes. J Immunol 2012, 189:33-37.
45. Wang C., Wu L., Bulek K., et al. The psoriasis-associated D10N variant of the adaptor Act1 with impaired regulation by the molecular chaperone hsp90. Nat Immunol 2013, 14:72-81.
46. Shi P., Zhu S., Lin Y., et al. Persistent stimulation with interleukin-17 desensitizes cells through SCFbeta-TrCP-mediated degradation of Act1. Sci Signal 2011, 4:ra73.
47. Shen F., Li N., Gade P., et al. IL-17 receptor signaling inhibits C/EBPbeta by sequential phosphorylation of the regulatory 2 domain. Sci Signal 2009, 2:ra8.
48. Yu X.H., Fu Y.C., Zhang D.W., et al. Foam cells in atherosclerosis. Clin Chim Acta 2013, 424:245-252.
49. Zhao G.J., Yin K., Fu Y.C., et al. The interaction of ApoA-I and ABCA1 triggers signal transduction pathways to mediate efflux of cellular lipids. Mol Med 2012, 18:149-158.
50. Li G., Gu H.M., Zhang D.W. ATP-binding cassette transporters and cholesterol translocation. IUBMB Life 2013, 65:505-512.
51. Cimato T.R., Palka B.A., Lang J.K., et al. LDL Cholesterol Modulates Human CD34+ HSPCs through Effects on Proliferation and the IL-17G-CSF Axis. PLoS One 2013, 8:e73861.
52. Yu X.H., Jiang H.L., Chen W.J., et al. Interleukin-18 and Interleukin-12 Together Downregulate ATP-Binding Cassette Transporter A1 Expression Through the Interleukin-18R/Nuclear Factor-kappaB Signaling Pathway in THP-1 Macrophage-Derived Foam Cells. Circ J 2012, 76:1780-1791.
53. Hao X.R., Cao D.L., Hu Y.W., et al. IFN-gamma down-regulates ABCA1 expression by inhibiting LXRalpha in a JAK/STAT signaling pathway-dependent manner. Atherosclerosis 2009, 203:417-428.
54. Zhang Z., Li X., Guo J., et al. Interleukin-17 enhances the production of interferon-gamma and tumour necrosis factor-alpha by bone marrow T lymphocytes from patients with lower risk myelodysplastic syndromes. Eur J Haematol 2013, 90:375-384.
55. Chen S., Shimada K., Zhang W., et al. IL-17A is proatherogenic in high-fat diet-induced and Chlamydia pneumoniae infection-accelerated atherosclerosis in mice. J Immunol 2010, 185:5619-5627.
56. Bohdanowicz M., Grinstein S. Role of phospholipids in endocytosis, phagocytosis, and macropinocytosis. Physiol Rev 2013, 93:69-106.
57. Michael D.R., Ashlin T.G., Davies C.S., et al. Differential regulation of macropinocytosis in macrophages by cytokines: Implications for foam cell formation and atherosclerosis. Cytokine 2013, 64:357-361.
58. Fang Y., Sang H., Yuan N., et al. Ethanolic extract of propolis inhibits atherosclerosis in ApoE-knockout mice. Lipids Health Dis 2013, 12:123.
59. Danzaki K., Matsui Y., Ikesue M., et al. Interleukin-17A deficiency accelerates unstable atherosclerotic plaque formation in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2012, 32:273-280.
60. Gistera A., Robertson A.K., Andersson J., et al. Transforming Growth Factor-beta Signaling in T Cells Promotes Stabilization of Atherosclerotic Plaques Through an Interleukin-17-Dependent Pathway. Sci Transl Med 2013, 5:196ra100.
61. Erbel C., Dengler T.J., Wangler S., et al. Expression of IL-17A in human atherosclerotic lesions is associated with increased inflammation and plaque vulnerability. Basic Res Cardiol 2011, 106:125-134.
62. Liu Z., Lu F., Pan H., et al. Correlation of peripheral Th17 cells and Th17-associated cytokines to the severity of carotid artery plaque and its clinical implication. Atherosclerosis 2012, 221:232-241.
63. Zhang X., Pei F., Zhang M., et al. Interleukin-17A gene variants and risk of coronary artery disease: a large angiography-based study. Clin Chim Acta 2011, 412:327-331.
64. Gao Q., Jiang Y., Dai S., et al. Interleukin 17A exacerbates atherosclerosis by promoting fatty acid-binding protein 4-mediated ER stress in macrophages. Circ Res 2013, 112:e87.
65. Zhu F., Wang Q., Guo C., et al. IL-17 induces apoptosis of vascular endothelial cells: a potential mechanism for human acute coronary syndrome. Clin Immunol 2011, 141:152-160.
66. Usui F., Kimura H., Ohshiro T., et al. Interleukin-17 deficiency reduced vascular inflammation and development of atherosclerosis in Western diet-induced apoE-deficient mice. Biochem Biophys Res Commun 2012, 420:72-77.
67. Smith E., Prasad K.M., Butcher M., et al. Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice. Circulation 2010, 121:1746-1755.
68. Butcher M.J., Gjurich B.N., Phillips T., et al. The IL-17A/IL-17RA axis plays a proatherogenic role via the regulation of aortic myeloid cell recruitment. Circ Res 2012, 110:675-687.
69. Ge S., Hertel B., Koltsova E.K., et al. Increased Atherosclerotic Lesion Formation and Vascular Leukocyte Accumulation in Renal Impairment are Mediated by Interleukin 17A. Circ Res 2013, 113:965-974.
70. van Es T., van Puijvelde G.H., Ramos O.H., et al. Attenuated atherosclerosis upon IL-17R signaling disruption in LDLr deficient mice. Biochem Biophys Res Commun 2009, 388:261-265.
71. Cheng X., Taleb S., Wang J., et al. Inhibition of IL-17A in atherosclerosis. Atherosclerosis 2011, 215:471-474.
72. Madhur M.S., Funt S.A., Li L., et al. Role of interleukin 17 in inflammation, atherosclerosis, and vascular function in apolipoprotein e-deficient mice. Arterioscler Thromb Vasc Biol 2011, 31:1565-1572.
73. Baeten D., Baraliakos X., Braun J., et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 2013, 382:1705-1713.
74. Leonardi C., Matheson R., Zachariae C., et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012, 366:1190-1199.
75. Papp K.A., Reid C., Foley P., et al. Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial. J Invest Dermatol 2012, 132:2466-2469.